These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 3081293)

  • 21. The pharmacokinetics of remoxipride and metabolites in patients with various degrees of renal function.
    Movin-Osswald G; Boelaert J; Hammarlund-Udenaes M; Nilsson LB
    Br J Clin Pharmacol; 1993 Jun; 35(6):615-22. PubMed ID: 8329289
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of glyburide.
    Pearson JG
    Am J Med; 1985 Sep; 79(3B):67-71. PubMed ID: 3931464
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationship between renal function and disposition of oral cefixime.
    Dhib M; Moulin B; Leroy A; Hameau B; Godin M; Johannides R; Fillastre JP
    Eur J Clin Pharmacol; 1991; 41(6):579-83. PubMed ID: 1815970
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A study to evaluate the pharmacokinetics of oral 5-fluorouracil and eniluracil after concurrent administration to patients with refractory solid tumours and varying degrees of renal impairment (FUMA1005).
    O'Donnell A; Punt CJ; Judson I; Van Maanen L; Suttle AB; Ertel P; Beale P
    Cancer Chemother Pharmacol; 2003 Jan; 51(1):58-66. PubMed ID: 12497207
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of beta-methyldigoxin in subjects with normal and impaired renal function.
    Tsutsumi K; Nakashima H; Tateishi T; Imagawa M; Nakano S
    J Clin Pharmacol; 1993 Feb; 33(2):154-60. PubMed ID: 8440765
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of renal impairment on the pharmacokinetics of intravenous zanamivir.
    Cass LM; Efthymiopoulos C; Marsh J; Bye A
    Clin Pharmacokinet; 1999; 36 Suppl 1():13-9. PubMed ID: 10429836
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment.
    Gschwend S; Ebert W; Schultze-Mosgau M; Breuer J
    Invest Radiol; 2011 Sep; 46(9):556-66. PubMed ID: 21623212
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Disposition of roxithromycin in patients with normal and severely impaired renal function.
    Halstenson CE; Opsahl JA; Schwenk MH; Kovarik JM; Puri SK; Ho I; Matzke GR
    Antimicrob Agents Chemother; 1990 Mar; 34(3):385-9. PubMed ID: 2334149
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Disposition kinetics of amikacin in patients with renal impairment after intramuscular administration.
    Lanao JM; Dominguez-Gil A; Tabernero JM; Molina HD
    Int J Clin Pharmacol Ther Toxicol; 1982 Jun; 20(6):271-5. PubMed ID: 7107075
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of oral and intravenous dolasetron mesylate in patients with renal impairment.
    Dimmitt DC; Shah AK; Arumugham T; Cramer MB; Halstenson C; Horton M; Weir SJ
    J Clin Pharmacol; 1998 Sep; 38(9):798-806. PubMed ID: 9753207
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of ceftazidime in patients with renal insufficiency.
    Welage LS; Schultz RW; Schentag JJ
    Antimicrob Agents Chemother; 1984 Feb; 25(2):201-4. PubMed ID: 6370127
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics and safety of single-dose ribavirin in patients with chronic renal impairment.
    Gupta SK; Kantesaria B; Glue P
    Drug Discov Ther; 2013 Aug; 7(4):158-63. PubMed ID: 24071578
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of renal impairment on the pharmacokinetics of cilostazol and its metabolites.
    Mallikaarjun S; Forbes WP; Bramer SL
    Clin Pharmacokinet; 1999; 37 Suppl 2():33-40. PubMed ID: 10702885
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of renal impairment on the pharmacokinetics of levomilnacipran following a single oral dose of levomilnacipran extended-release capsule in humans.
    Chen L; Greenberg WM; Brand-Schieber E; Wangsa J; Periclou A; Ghahramani P
    Drug Des Devel Ther; 2015; 9():3293-300. PubMed ID: 26150701
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Single-dose pharmacokinetics of pravastatin and metabolites in patients with renal impairment.
    Halstenson CE; Triscari J; DeVault A; Shapiro B; Keane W; Pan H
    J Clin Pharmacol; 1992 Feb; 32(2):124-32. PubMed ID: 1613121
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effects of renal impairment on the pharmacokinetics and safety of fosfluconazole and fluconazole following a single intravenous bolus injection of fosfluconazole.
    Sobue S; Tan K; Layton G; Leclerc V; Weil A
    Br J Clin Pharmacol; 2004 Jun; 57(6):773-84. PubMed ID: 15151523
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function.
    Ikeda M; Furukawa H; Imamura H; Shimizu J; Ishida H; Masutani S; Tatsuta M; Kawasaki T; Satomi T
    Cancer Chemother Pharmacol; 2002 Jul; 50(1):25-32. PubMed ID: 12111108
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of oral cefatrizine in patients with impaired renal function.
    Couet W; Fauvel JP; Laville M; Pozet N; Fourtillan JB
    Int J Clin Pharmacol Ther Toxicol; 1991 Jun; 29(6):213-7. PubMed ID: 1869342
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetic study of the new sulfamethopyrazine-trimethoprim combination (kelfiprim) in renal insufficiency.
    Cantaluppi A; Graziani G; Ponticelli C; Grasso S; Meinardi G; Piaia F; Tamassia V
    Eur J Clin Pharmacol; 1984; 27(3):345-8. PubMed ID: 6510463
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kidney function.
    Webb DB; Roberts DE; Williams JD; Asscher AW
    J Antimicrob Chemother; 1986 Nov; 18 Suppl D():83-7. PubMed ID: 3804907
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.